Bone health after diagnosis of breast cancer

CMAJ. 2018 Dec 10;190(49):E1452. doi: 10.1503/cmaj.180802.

Authors

Shannon M Ruzycki¹, Nancy A Nixon²

Affiliations

¹ Department of Medicine (Ruzycki), University of Calgary; Department of Oncology (Nixon), Tom Baker Cancer Centre, Calgary, Alta. sarro@ualberta.ca.
² Department of Medicine (Ruzycki), University of Calgary; Department of Oncology (Nixon), Tom Baker Cancer Centre, Calgary, Alta.

No abstract available

MeSH terms

Aromatase Inhibitors / adverse effects*
Bone Density Conservation Agents / therapeutic use
Bone Neoplasms / drug therapy
Bone Neoplasms / prevention & control
Bone Neoplasms / secondary*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Diphosphonates / therapeutic use
Female
Humans
Neoplasm Staging
Osteoporosis / chemically induced*
Osteoporosis / drug therapy
Osteoporotic Fractures / prevention & control*
Postmenopause
Premenopause
Risk Assessment
Survival Rate

Substances

Aromatase Inhibitors
Bone Density Conservation Agents
Diphosphonates